Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

NCT05668585 is registered in ClinicalTrials.gov with C4 Therapeutics, Inc. as lead sponsor.

NCT NCT05668585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05668585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
Lead sponsor
C4 Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 8, 2022
Completion date
November 5, 2025
Enrollment
89 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

atc, crc, melanoma, nsclc, solid tumors